Immunicum AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.02.19	Immunicum AB (publ) Announces Upcoming Investor Events in February (GlobeNewswire)
31.01.19	Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue (GlobeNewswire)
30.01.19	Changes to the Nomination Committee for Immunicum AB (publ) (GlobeNewswire)
22.01.19	Immunicum AB (publ) Announces Upcoming Investor Events in January (GlobeNewswire)
21.01.19	Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology (GlobeNewswire)
28.12.18	Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Directed Issue (GlobeNewswire)
13.12.18	Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M (GlobeNewswire)
23.11.18	Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue (GlobeNewswire)
16.11.18	Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study (GlobeNewswire)
08.11.18	Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018 (GlobeNewswire)
07.11.18	Immunicum AB (publ) Interim Report July - September 2018 (GlobeNewswire)
24.10.18	Immunicum AB: Invitation to Investor Events in Gothenburg and Stockholm (GlobeNewswire)
22.10.18	Immunicum AB (publ) Announces Upcoming Investor Events in October and November (GlobeNewswire)
22.10.18	Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 (GlobeNewswire)
19.10.18	Immunicum AB (publ) Announces Nomination Committee for AGM 2019 (GlobeNewswire)
16.10.18	Immunicum AB (publ) Clarifies Information Regarding Directed Issue (GlobeNewswire)
16.10.18	Notice of Extraordinary General Meeting in Immunicum AB (publ) (GlobeNewswire)
16.10.18	Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy (GlobeNewswire)
01.10.18	Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration (GlobeNewswire)
27.09.18	Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October (GlobeNewswire)
17.09.18	Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board (GlobeNewswire)
17.08.18	Immunicum AB (publ) Interim Report April - June 2018 (GlobeNewswire)
13.08.18	Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress (GlobeNewswire)
23.07.18	Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial (GlobeNewswire)
18.06.18	Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	524.80	1.59 %	K V
Alcon	77.04	1.50 %	K V
UBS Group	28.37	0.82 %	K V
Lonza Grp	525.20	0.69 %	K V
Kuehne+Nagel Int	208.90	0.43 %	K V
Nestle	76.24	0.37 %	K V
Swisscom	505.50	0.00 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Immunicum AB

Aktien Top/Flop

Meistgelesene Nachrichten